Antiepileptic Drug Development: I. History and a Program for Progress

Epilepsia

Volumn 19, Issue 4, 1978, Pages 393-407

  Krall, R L ^a   Penry, J K ^a   Kupferberg, H J ^a   Swinyard, E A ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Anticonvulsant drill's; Antiepileptic drugs; Development; Epilepsy; History

Indexed keywords

AMINOGLUTETHIMIDE; ANTICONVULSIVE AGENT; BECLAMIDE; CARBAMAZEPINE; CEFONTIN; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETHOTOIN; MEPHENYTOIN; MESUXIMIDE; METHARBITAL; METHYLPHENOBARBITAL; PARAMETHADIONE; PEGANONE; PHENACEMIDE; PHENOBARBITAL; PHENSUXIMIDE; PHENYTOIN; PRIMIDONE; THYPHENYTOIN; TRIMETHADIONE; UNCLASSIFIED DRUG; VALPROIC ACID;

CENTRAL NERVOUS SYSTEM; DRUG DESIGN; DRUG RESEARCH; DRUG THERAPY; ECONOMIC ASPECT; EPILEPSY; THERAPY; THYPHENYTOIN;

ANTICONVULSANTS; BROMIDES; DRUG COMPOUNDING; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HISTORY OF MEDICINE, 19TH CENT.; HISTORY OF MEDICINE, 20TH CENT.; KINETICS; NATIONAL INSTITUTES OF HEALTH (U.S.); PHENOBARBITAL; PHENYTOIN; RESEARCH SUPPORT; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, U.S. GOV'T, P.H.S.; UNITED STATES;

EID: 0018189181     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1978.tb04506.x     Document Type: Article

References (74)

1. Untersuchungen (iberdie Wirkungeiniger Arzneimittel auf die Erregbarkeit des Grosshirns nebst Beitragen zur Therapie der Epilepsie
2. Die Bekampfung epileptischer Anfalle und ihrer Folgeerscheinungen mit Prominal
3. Comparative assay of antiepileptic drugs by “psychomotor” seizure test and minimal elec‐troshock threshold test.
4. Ethosuximide in the treatment of absence (petit mal) seizures
5. Epidemiology of epilepsy
6. Other hydan‐toins: Albutoin
7. Evaluation of albutoin as an antiepileptic drug
8. Carbamazepine for epilepsy. A controlled prospective evaluation
9. General principles. Testing of anticonvulsants in man
10. The anticonvulsant activity of a‐phenyl succini‐mides
11. Anticonvulsant activity and toxicity of phensuximide, meth‐suximide and ethosuximide
12. The effect of trimethyl‐oxazolidine dione and of dimethylethyloxazolidine dione on seizures and on the blood
13. Effects of sulthiame upon intellectual, neuropsychological, and social functioning abilities among adult epileptics: Comparison with diphenyl‐hydantoin
14. Serum clonazepam concentrations in children with absence seizures
15. Comparative anticonvulsive action of 3,5,5‐trimethyloxazolidine‐2,4‐dione (Tridione), Dilantin and phenobarbital
16. Clinical and electroencephalographical classification of epileptic seizures
17. Phenurone in epilepsy
18. Comparison of maximal seizures evoked by pentylenetetrazol (Metrazol) and electroshock in mice, and their modification by anticonvulsants
19. Laboratory technics for the identification and evaluation of potentially antiepileptic drugs
20. Anticonvulsant drugs: Mechanisms of action and methods of assay
21. Sulthiame: Evaluation as an anticonvulsant
22. Luminal bei Epilepsie
23. Pentamethylentetrazol (Cardiazol). I. Mitteilung.
24. Observations in electric shock therapy applied to problems of epilepsy
25. Quantitative structure‐activity relationships of anticonvulsant drugs
26. Antiepileptic drug development: II. Anticonvulsant drug screening
27. GLC determination of carbamazepine in plasma
28. The development of a matrix reference standard for antiepileptic analysis
29. Usefulness of blood levels of antiepileptic drugs
30. Tridione in the treatment of epilepsy
31. The petit mal epilepsies. Their treatment with Tridione
32. Pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration
33. Motor seizure telemetry and initial data in free‐roaming monkey model with spontaneous seizures
34. Behavioral experimental epilepsy in monkeys. I. Clinical seizure recording apparatus and initial data
35. Pharmacokinetic evaluation of anticonvulsants prior to efficacy testing exemplified by carbamazepine in epileptic monkey model
36. Efficacy of standard anticonvulsants in monkey model with spontaneous motor seizures
37. Discussion of a paper by EH Sieveking. Analysis of 52 cases of epilepsy observed by the author
38. Studies in new anticonvulsants
39. Sodium diphenyl hydan‐toinate in the treatment of convulsive disorders
40. Experimental determination of anticonvulsive activity of chemical compounds
41. A new series of antconvulsant drugs tested by experiments on animals
42. Proprietes pharmacodynamiques de Tacide n‐dipropylacetique
43. Report on five years' use of prominal as routine treatment for epileptics
44. Prominal in epilepsy
45. Principles for clinical testing of antiepileptic drugs
46. Interlaboratory variability in determination of plasma antiepileptic drug concentrations
47. Diagnostic and therapeutic reevaluation of patients with intractable epilepsy
48. The clinical efficacy and pharmacokinetics of phensuximide and methsuximide
49. Acute hepatic necrosis with death occurring during phe‐thenylate sodium therapy: Report of two cases
50. Experimental determination of the anticonvulsant properties of some phenyl derivatives
51. Analgesic and anticonvulsive properties of 3,5,5‐trimethyloxazolidine‐2, 4‐dione (Tridione)
52. Prevalence of epilepsy in children
53. Quantitative determination of the convulsive reactivity by electrical stimulation of the brain with the skull ii ct
54. Some inalgesic âgents derived from oxazolidine‐2,4‐dic
55. Metrazol convulsions and their relation to the epileptic attack
56. Laboratory assay of clinically effective antiepileptic drugs
57. The search for new drugs against epilepsy
58. Properties of maximal seizures, and their alteration by anticonvulsant drugs and other âgents
59. Pharmakologie des Prominal
60. Electroencephalographic investigations during evaluation of the antiepileptic âgent sulthiame
61. A new drug for petit mal epilepsy